Transgene Biotek Appoints New Statutory Auditor

Incoming Auditor: M/s. Ranganath Prasad & Co. | Effective Date: November 4, 2026

Reader Takeaway: The auditor change is due to personal circumstances, but timely completion of Q2 financial results is crucial.

What just happened

Transgene Biotek Ltd has formally appointed M/s. Ranganath Prasad & Co. to fill the casual vacancy created by the sudden resignation of its former statutory auditor, M/s. Harish Gummadi & Co. The outgoing auditor cited an unforeseen medical emergency within their immediate family as the primary reason for their inability to commit the necessary resources to complete the Limited Review of the company’s September 30, 2026, quarterly financial results.

Why this matters

Statutory auditors play a critical role in verifying financial integrity and ensuring regulatory compliance. The resignation occurred just ahead of the filing deadline for the second quarter, making the prompt appointment of a successor essential to avoid any potential lapse in regulatory reporting. The incoming firm, Ranganath Prasad & Co., has confirmed its eligibility and consent to take over the mandate.

What changes now

While the appointment is effective as of November 4, 2026, it remains subject to formal approval by shareholders at a general meeting that must be held within the next three months. The company has moved quickly to address the vacancy, ensuring that audit, assurance, and tax compliance functions remain uninterrupted.

Risks to watch

Investors should look for the timely release of the financial results for the quarter ended September 30, 2026. Any further delay in filing or potential qualifications by the new auditor regarding the transition period could be a point of concern for market participants.

What to track next

The next key milestone will be the convening of the general meeting to ratify the appointment and the successful submission of the September quarter financial results under the review of the newly appointed firm.